Welcome to our dedicated page for Cencora SEC filings (Ticker: COR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cencora, Inc. (NYSE: COR) SEC filings page on Stock Titan provides centralized access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a large pharmaceutical solutions and distribution organization, Cencora uses its SEC reports to present detailed information about its financial performance, capital structure, governance, and significant transactions.
Investors can review Form 10-K annual reports and Form 10-Q quarterly reports to understand Cencora’s revenue composition, segment performance for U.S. Healthcare Solutions and International Healthcare Solutions, and the impact of acquisitions such as Retina Consultants of America. These filings also describe non-GAAP measures like adjusted operating income and adjusted diluted earnings per share, along with reconciliations to GAAP metrics.
Cencora’s Form 8-K current reports offer timely updates on material events, including amendments to credit facilities, changes to its receivables securitization program, issuance and listing of senior notes, revisions to its reporting structure, and agreements to acquire additional equity interests in OneOncology. Other 8-Ks disclose governance developments, such as board appointments and leadership changes, as well as information about legal settlements and derivative actions.
Through Stock Titan, users can also track registered debt securities like Cencora’s 2.875% Senior Notes due 2028 (COR28) and 3.625% Senior Notes due 2032 (COR32), which are listed alongside the common stock. Where available, insider transaction reports on Forms 3, 4, and 5 can help users monitor equity ownership changes by directors and officers.
AI-powered tools on the platform summarize lengthy Cencora filings, highlight key changes from prior periods, and surface important disclosures about liquidity, financing arrangements, segment realignments, and legal matters. This helps readers quickly interpret complex documents and focus on the sections most relevant to their analysis of COR.
Cencora, Inc. (COR) reported insider activity by Executive Vice President Silvana Battaglia on 11/07/2025. Two restricted stock unit (RSU) tranches vested and were settled into common stock (codes M) for 1,265 shares and 1,084 shares. To cover tax withholding, she had broker-assisted sales (code F) of 551 shares and 473 shares at $360.70 per share. After these transactions, she directly owned 12,674.464 common shares.
The footnotes state the first RSU grant vested in three equal annual installments on 11/9/2023, 11/9/2024, and 11/9/2025, and the second RSU grant vests on 11/08/2024, 11/08/2025, and 11/08/2026. The 2023 grant is fully settled; 1,085 RSUs from the 2024 grant remain outstanding.
Cencora (COR) reported insider activity by an Executive Vice President. On 11/07/2025, two restricted stock unit tranches converted to common stock: 2,023 shares and 1,830 shares (coded “M”). To cover taxes, the filer disposed of 798 shares and 572 shares at $360.7 per share (coded “F”). Following these transactions, directly beneficially owned common stock stood at 15,307.141 shares. The vesting schedules referenced cover installments on 11/09/2023–2025 and 11/08/2024–2026.
Cencora (COR) reported a Form 4 for CFO James F. Cleary reflecting RSU vesting and tax withholding on 11/07/2025. Two RSU tranches converted to common stock: 2,951 shares and 2,439 shares (codes M). To satisfy withholding taxes, the company withheld and disposed of 1,250 shares and 705 shares at $360.7 per share (code F). Following these transactions, Cleary’s directly held common stock totaled 117,728.3479 shares.
The vested RSUs relate to grants scheduled to vest in equal annual installments on 11/9/2023–11/9/2025 and 11/08/2024–11/08/2026, as noted in the filing.
Cencora (COR) reported insider activity by its SVP & Chief Accounting Officer. On 11/07/2025, two restricted stock unit (RSU) tranches vested and were settled into common stock: 1,433 shares and 1,398 shares (both at $0 exercise price).
To cover withholding taxes tied to the vesting, the insider disposed of 411 shares and 366 shares at $360.7 per share. Following these transactions, the insider directly holds 19,208 shares of common stock. The RSUs relate to grants vesting in equal annual installments on 11/09/2023–11/09/2025 and 11/08/2024–11/08/2026.
Cencora, Inc. (COR) reported insider activity by President & CEO and Director Robert P. Mauch on 11/07/2025. Two restricted stock unit (RSU) tranches vested and were settled into common stock: 4,215 shares and 4,065 shares (codes M). To cover taxes upon vesting, the filer disposed of 1,735 shares and 1,673 shares at $360.70 per share (code F). After these transactions, Mauch directly beneficially owns 42,812 shares.
Footnotes indicate the RSUs were granted for no consideration and vest in three equal annual installments tied to November 2023–2026 dates.
COR insider Steven Collis filed a Form 144 to sell up to 50,000 common shares through Fidelity Brokerage Services on or about 11/06/2025, to be sold on the NYSE. The filing lists an aggregate market value of $17,762,553.74 and notes 193,877,881 shares outstanding. The shares derive from restricted stock vesting on 11/12/2014, 11/11/2015, 08/07/2016, 11/11/2018, and 11/14/2018. In the past three months, Collis sold 14,579, 31,350, and 31,350 shares for gross proceeds of $4,227,618.42, $9,087,157.00, and $10,251,104.58, respectively.
Cencora, Inc. (COR) filed an 8‑K announcing its earnings release for the fiscal quarter and year ended September 30, 2025, with the news release furnished as Exhibit 99.1. The company also unveiled a new reporting structure to be used beginning in the first quarter of fiscal 2026: U.S. Healthcare Solutions; International Healthcare Solutions; and Other.
U.S. Healthcare Solutions will include U.S. Human Health (excluding legacy U.S. Consulting Services). International Healthcare Solutions will include Alliance Healthcare, Innomar, World Courier, and strategic components of PharmaLex. Other will include businesses for which Cencora has begun to explore strategic alternatives, including MWI Animal Health, Profarma, U.S. Consulting Services, and the other components of PharmaLex. Unaudited revised segment information is furnished as Exhibit 99.2. The company scheduled a conference call and webcast at 8:30 a.m. Eastern time.
Cencora (COR) reported insider equity activity. On 10/31/2025, EVP and Chief Data & Info Officer Pawan Verma settled 8,537 restricted stock units into common stock (transaction code M). To satisfy tax withholding, 4,367 shares were disposed (transaction code F), both at a listed price of $337.81 per share. After these transactions, Verma directly owned 4,184.05 shares.
Cencora (COR) reported an insider equity grant. Director Werner Baumann acquired 108 shares of common stock on 11/01/2025, shown at $337.81 per share, bringing his directly held balance to 3,130 shares.
The filing notes this was a grant of restricted stock units in lieu of a $36,250 quarterly cash retainer under the company’s Non‑Employee Director Compensation Program, with delivery of shares deferred until 02/15/2028.
Cencora (COR) reported an insider transaction by a director. On 11/01/2025, the director acquired 89 shares of common stock at $337.81 per share. Following this transaction, beneficial ownership stands at 3,069 shares, held directly.
The filing notes the shares reflect a grant of restricted stock units received in lieu of a $30,000 quarterly cash retainer under the company’s Non-Employee Director Compensation Program.